Conference Coverage

The field of sports cardiology has experienced remarkable growth, with new guidelines, expanding programs, and increasing recognition of cardiovascular risk in athletes. Hear from Dr. Jeffrey Hsu as he shares current and emerging approaches to risk assessment, prevention, and management of cardiac conditions in this population. Dr. Hsu is a Clinical Assistant Professor of Medicine at the David Geffen School of Medicine at UCLA, and he spoke about this topic at the 2026 American College of Cardiology (ACC) Scientific Sessions.

Early real-world experience with the 2024 McDonald criteria suggests a meaningful increase in multiple sclerosis (MS) diagnoses, driven largely by recognition of optic nerve involvement and reclassification of radiologically isolated syndrome. Hear from Dr. Aaron Miller as he reviews emerging evidence, explains how these updates are reshaping diagnostic pathways, and addresses practical challenges in implementation. Dr. Miller is the Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis and a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York. He also spoke about this topic at the 2026 American Academy of Neurology (AAN) Annual Meeting.

Multiple sclerosis (MS) is often diagnosed during peak reproductive years, making proactive, informed care essential across the lifespan. Hear from Dr. Riley Bove as she discusses the importance of early, ongoing conversations about fertility, pregnancy, and menopause in this population. Dr. Bove is an Associate Professor at UCSF Weill Institute for Neurosciences, and she discussed this topic at the 2026 American Academy of Neurology (AAN) Annual Meeting.

Hear from Dr. Aaron Miller as he shares important updates in multiple sclerosis (MS) at the 2026 American Academy of Neurology (AAN) Annual Meeting. Dr. Miller is the Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis and a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York.

At the 2026 American Academy of Neurology (AAN) Annual Meeting, experts are sharing the latest developments in pediatric multiple sclerosis (MS). Dr. Elizabeth Wilson is here to share insights on how new adult MS research, neuro-ophthalmology collaboration, and emerging clinical data are shaping the future of care. Dr. Wilson is the Director of the Multiple Sclerosis and Neuroimmunology Center at Cincinnati Children's Hospital.

Emerging research is redefining the role of the gut microbiome in food allergy and immune tolerance. Here to share some of the most groundbreaking findings is Dr. Mustafa Ozcam. He discusses how gut microbes metabolize allergenic proteins, shape immune development, and serve as potential biomarkers to predict oral immunotherapy success in food allergy patients. Dr. Ozcam is an Assistant Professor of Microbiology and Immunology at the University of Maryland School of Medicine, and he spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Financial and space limitations are two of the most pressing issues facing allergists and immunologists in academic practice. Fortunately, negotiation principles, like BATNA and ZOPA, and disruptive innovation tactics can help address these common issues. To learn more, we recently spoke with Dr. Marcus Shaker. Not only is he a Professor of Pediatrics and Medicine at the Dartmouth Geisel School of Medicine in New Hampshire, but he also spoke about this topic at the 2026 American Academy of Allergy, Asthma, & Immunology Annual Meeting.

Given that severe asthma management is entering a new era of biologically driven precision, Dr. Sally Wenzel joins us to discuss the complexity within Type 2 inflammation and the limitations of relying on a single biomarker assessment. She also differentiates childhood-onset allergic asthma from adult-onset disease, underscoring how age of onset—along with underlying biology—can inform therapeutic strategy. Dr. Wenzel serves as the Director of the Asthma Institute at UPMC, and she spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Based on a randomized study, children with higher baseline thresholds of peanut reactivity achieved markedly higher rates of sustained unresponsiveness after oral immunotherapy compared with untreated peers. Learn more about this study and its clinical implications with Dr. Scott H. Sicherer. Not only is he a Professor of Pediatrics and the Director of the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai, but he also spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Multiplex proteomic biomarker panels are redefining how we understand and monitor multiple sclerosis (MS) by capturing interconnected pathways in a single sample. Hear from Dr. Raphael Schneider as he explores how these tools could inform prognosis, risk stratification, and clinical trial design, which he spoke about at the 2026 ACTRIMS Forum. Dr. Schneider is a neurologist and researcher at the BARLO MS Centre at St. Michael’s Hospital as well as an Assistant Professor and the Elizabeth S. Barford Early Career Professor in Multiple Sclerosis in the Department of Medicine at the University of Toronto.